Tiziano Barbui

Oct 7, 2024 | onlinelibrary.wiley.com | Tiziano Barbui |Alessandra Carobbio |Paola Guglielmelli |Arianna Ghirardi

CONFLICT OF INTEREST STATEMENT No conflicts of interest were declared. Supporting Information Filename Description bjh19813-sup-0001-TableS1.docxWord 2007 document , 27.8 KB Table S1. REFERENCES 1, , , , , , et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140: 1200–1228. 2, , , , , , et al.

May 18, 2024 | onlinelibrary.wiley.com | Tiziano Barbui

Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of UseUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.

May 17, 2024 | onlinelibrary.wiley.com | Ayalew Tefferi |Tiziano Barbui

• , , , et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data . Blood. ; : - . • , , , et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger . Am J Hematol. ; : - . • , , , , . Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995 . Am J Hematol. ; : - . • , , , et al.

Jan 26, 2024 | onlinelibrary.wiley.com | Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

1 DISEASE CLASSIFICATION AND INCIDENCE Essential thrombocythemia (ET) is one of four Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasms (MPNs), which also include polycythemia vera (PV), primary myelofibrosis (PMF), and MPN, unclassifiable (MPN-U).1-3 In addition, about 15% of patients with ET or PV develop a PMF-like phenotype, over time, referred to as post-ET or post-PV MF.4 MPNs are included in the 2022 International Consensus Classification (ICC) category of myeloid...

Jun 27, 2023 | onlinelibrary.wiley.com | Ayalew Tefferi |Tiziano Barbui

8.2.1 Recommendations In general, we prefer to avoid cytoreductive therapy in low-risk PV, including those aged 40–60 year,96 in the absence of clear evidence for disease modification or value in meaningful health outcome (i.e., survival, fibrotic progression, thrombosis, quality of life). Most patients tolerate phlebotomy well and prefer to avoid drug therapy, other than aspirin unless it is curative.